Andrew Johnson
Analyst · Gabelli & Company. Please go ahead
Thanks, Stacey, and good morning, everyone. Thank you for joining us today. The last few months can be characterized by our progress for scores that we have identified as critical to our organizational advancement, profitability, and long-term sustainable growth. We are undertaking an extensive review of the company and our strategy. We are taking steps to better prioritize our resources and reduce costs. We have taken targeted measures that include the consolidation of our facilities, headcount reductions and company-wide synergies. At the same time, we are investing in areas that we believe are meaningful opportunities in professional and industrial verticals. In December, we made a significant step for our shipped away from consumer activities, including end-of-life of the Cube 3 and the discontinuation of cubify.com. This was a clear demonstration of our commitment to prioritize our resources towards meeting real customer demand in the marketplace. Then in January, we launched the ProX DMP 320, a high-precision, high-throughput printer designed for complex metal parts in titanium, stainless steel and nickel super alloys. The 320 is a powerful and reliable system, and we believe it gives us a strong foothold in key metals applications ranging from healthcare to industrial manufacturing to service center production. We are also introducing additional new products that extends our price points in capabilities from the product design lab to the factory floor, including the ProJet MJP 3600 and the ProJet MJP 2500. We showed our continued commitment to innovation through the demonstration of our Figure 4 SOA Technology at CES earlier this year. One of the features of Figure 4 is that it could be housed in discreet modules, allowing it to be integrated into an automated manufacturing environment at a scale of one up to a large array of hundreds. It also capable of manufacturing parts in hybrid materials that are tough, durable, temperature resistant and elastomeric. And just last week we celebrated the opening of our healthcare technology center in Denver, Colorado, a state of the art facility that serves as essential help for all of our healthcare activities from surgical simulation to virtual surgical planning, to device design and manufacturing. Maintaining the competitive product portfolio to meet evolving market demand is a top priority for us, and we are reviewing each of our product lines and business activities. We believe that a comprehensive review of our business and strategy is necessary to our success, particularly as we face continued uncertainty in the market. We are probably in the midst of this extensive business review. The executive management committee which as a reminder includes Chuck Hull, our Founder, Director and Chief Technology Officer, who chairs the committee; Dave Styka, our Chief Financial Officer; Mark Wright, our Chief Operating Officer; and myself continues to provide oversight and guidance in day-to-day operations in review of the company's strategy. Our leadership team and employees throughout the company has stepped up and are contributing to delivering improvements while insuring the effectiveness of our operations company-wide. Our commitment to quality in our people, processes and products has been apparent internally for the last several months. The executive management committee has been building a culture based on transparency, accountability and collaboration within our organization. This is manifesting itself in continue of business process improvement and enhanced new product launches and overall customer experience. We believe quality in people, business processes in products will help drive customer and employee satisfaction and improved productivity and business results. Additionally, we kicked our comprehensive partner program, Partner Xcel, at a global partner summit in January. Both Partner Xcel and the summit itself reflected commitments and investments we are making in our partners and in our sales organization, as well as the commitments our partners are making in 3D Systems. I believe our partners and our internal sales team walked away from the summit with a renewed sense of trust, appreciation and confidence of our partner model and in our company. Meanwhile, our Board of Directors is continuing the process to name the permanent CEO and the search committee is pleased with the progress today. Although we are in a transitional period, we are not sitting still. We recognize that developments in our industry have brought heightened competition and new challenges, but there are also significant and exciting opportunities. We are taking steps to position ourselves to capitalize on those opportunities through a comprehensive review of our products, activities and strategy. And with that, I'd like to turn to an overview of fourth quarter results. Revenue decreased 2% from the fourth quarter of 2014 to $183.4 million. We are pleased with the revenue in the fourth quarter of 2015 which benefitted from the timing of orders from healthcare and industrial customers, as well as contributions from acquisitions. Despite our 21% sequential improvement in revenue, industry conditions remain challenging and we may continue to experience uneven demand in the coming periods. Gross profit margin decreased to 32.8% driven by the impact of charges related to our ship away from consumer. Excluding those charges, gross profit margin was 47.7% compared to 47.9% in the fourth quarter of 2014. Cash operating expenses of $66.7 million remained flat sequentially. We reported a fourth quarter GAAP net loss of $596.4 million, a loss of $5.32 per share and a non-GAAP net income of $20.9 million or $0.19 earnings per share. Now, I'd like to turn the call over to our CFO, Dave Styka, for more details on these results. Dave?